AstraZeneca: encouraging results for Tagrisso
(CercleFinance.com) - AstraZeneca has announced that a phase III trial has showed that Tagrisso (osimertinib) produced a statistically and clinically significant improvement in overall survival (OS) compared to placebo in the adjuvant treatment of patients with early stage (IB, II and IIIA) epidermal growth factor receptor (EGFRm)-mutated non-small cell lung cancer (NSCLC) after complete curative tumour resection.
The results of this study provide strong evidence that osimertinib offers the best possible care for patients with early stage EGFR-mutated non-small cell lung cancer who have historically faced high recurrence rates and previously had no targeted options after surgery, a related medical source noted.
In addition, the safety and tolerability of Tagrisso in the trial was consistent with its established profile and no new safety issues were reported.
Copyright (c) 2023 CercleFinance.com. All rights reserved.